SGLT2 inhibitors are linked to consequences, including genitourinary infections (GUIs), particularly urinary tract infections (UTIs) and vulvovaginitis, due to their promotion of glucosuria [15,16]. The gene discussed is SLC5A2; the disease is urinary tract infection.